Digest Network Come funziona
Network
/
Società
Sh
Non verificato

Shionogi USA

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteScienza

15 comunicati stampa

Guarda tutti i comunicati
16/04/2026
Eventi
Industria
Scienza
Telefonia e Varie
Tecnica
Attrezzature medico-sanitarie
Biotecnologia
Farmaceutica
Salute
Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
08/04/2026
Mercato del lavoro
Industria
Scienza
Politica Interna
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
07/04/2026
Eventi
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
01/04/2026
Mercato azionario
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
 Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
19/03/2026
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
22/12/2025
Igiene alimentare
Salute
Scienza
Farmaceutica
Biotecnologia
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
20/10/2025
Salute
Scienza
Sanità
Farmaceutica
Biotecnologia
Eventi
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
03/09/2025
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Eventi
Fiere
Industria
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
02/09/2025
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
12/03/2025
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0